Investigation by Berger Montague PC
Berger Montague PC, a renowned national plaintiffs' law firm, is initiating an investigation concerning a class action lawsuit related to Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). This initiative aims to support investors who purchased common stock of Ultragenyx within a specific timeframe during which critical information about the company was misrepresented.
Background on Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company dedicated to developing innovative therapies aimed at treating rare genetic diseases. Headquartered in Novato, California, Ultragenyx focuses on addressing serious health conditions that often lack effective treatment options. The company has drawn attention due to its promising pipeline of drugs, particularly those directed at Osteogenesis Imperfecta, a severe genetic disorder that greatly impacts bone strength.
Details of the Class Action Lawsuit
According to allegations in the lawsuit, Ultragenyx made several positive statements to investors regarding its clinical trials, specifically the ORBIT and COSMIC Phase 3 programs, which were intended to test the efficacy of setrusumab as a potential treatment for Osteogenesis Imperfecta. Such optimistic claims contributed to building investor confidence.
Shock and Impact on Investors
On December 29, 2025, a significant announcement from Ultragenyx revealed that neither of the mentioned studies successfully met its primary endpoint: reducing the annualized clinical fracture rate. This announcement caused a dramatic plummet in share prices, dropping more than 42%, from a closing price of $34.19 on December 26, 2025, to a startling close of $19.72 just days later.
Potential Actions for Investors
Investors who purchased shares during the specified period from August 3, 2023, to December 26, 2025, are encouraged to explore their rights regarding this class action lawsuit. Opportunities to become lead plaintiffs are available, with a filing deadline that requires prompt action. It is essential for investors to stay informed and understand their legal options.
Contact Information for Legal Assistance
Individuals seeking to learn more about their rights in this context can reach out to Berger Montague for further assistance and clarification. The firm’s seasoned team is available to provide information and answer any questions regarding the ongoing proceedings.
About Berger Montague
With a rich history spanning over 55 years, Berger Montague is recognized as one of the foremost law firms in the United States. The firm specializes in complex civil litigation, class actions, and mass torts, consistently achieving impressive outcomes for its clients. Berger Montague has successfully recovered over $50 billion for the classes it represents, establishing a reputation for excellence and dedication to client advocacy.
Frequently Asked Questions
What is the focus of the class action lawsuit against Ultragenyx?
The lawsuit centers on claims that Ultragenyx misled investors regarding the outcomes of its clinical trials, which significantly impacted stock prices.
Who can join the class action lawsuit?
Investors who purchased Ultragenyx stock during the specified class period may seek to join the lawsuit and represent their interests.
How does Berger Montague support affected investors?
Berger Montague provides legal assistance, helping investors understand their rights and navigate the class action process.
What impact did the recent announcement have on Ultragenyx's stock?
The announcement led to a sharp decline in Ultragenyx's stock price, reducing it by more than 42% within days.
What is the significance of the lead plaintiff role?
The lead plaintiff has the responsibility of representing the interests of all class members and can influence the direction of the case.
